Janssen withdraws attempt to extend Velcade indication in EUPMLiVEThe Johnson & Johnson division had submitted an application to the European Medicines Agency (EMA) in September 2011 to consider the drug's use in combination with rituximab for …
EMA: Janssen-Cilag has Withdrew Extension Application for VelcadeWall Street Journal2, 2011, submitted an application to extend the marketing authorization for Velcade in combination with rituximab for the treatment of patients with relapsed follicular…
Long-Term Rituximab Safe for Patients With Wegener'sDoctors LoungeRepeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiiti…
Long-term rituximab safe for patients with wegener'sMedical Xpress(HealthDay) — Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis w…
Cancer drug price droppedBizcommunity.comThe Department of Health has persuaded pharmaceutical company Roche to halve the price of its cancer drug rituximab, opening the way for the government to provide it to more patients. The drug belongs to an expe…
An efficient approach for rheumatoid arthritis managementPhilippine StarIn March 2011, Ribargoso started Santos on rituximab infusions. … Rituximab is a unique therapy for rheumatoid arthritis, specifically targeting the B cell — a …
Post (subscription)'Cancer drug price dropped'Post (subscription)The department's deputy director general for regulation Anban Pillay said the drug rituximab, dubbed MabThera by Roche, had previously been too expensive for the state to buy …
Independent Online'Cancer drug price dropped'Independent OnlineThe department's deputy director general for regulation Anban Pillay said the drug rituximab, dubbed MabThera by Roche, had previously been too expensive …State patients to be…
Cell Therapeutics Readies Commercial Launch of Pixuvri® in EU; Re-Alignment …Business Review India (press release)CTI is currently accruing patients into a Phase III trial comparing pixantrone and rituximab with gemcitabine and rituxan in the settin…
Cell Therapeutics Readies Commercial Launch of Pixuvri® in EU …MarketWatch (press release)CTI is currently accruing patients into a Phase III trial comparing pixantrone and rituximab with gemcitabine and rituxan in the setting of aggressive B-cell ….